title: Reduced Crystallization Temperature Methodology for Polymer Selection in Amorphous Solid Dispersions: Stability Perspective.
abstract: API-polymer interactions, used to select the right polymeric matrix with an aim to stabilize an amorphous dispersion, are routinely studied using spectroscopic and/or calorimetric techniques (i.e., melting point depression). An alternate selection tool has been explored to rank order polymers for formation of stable amorphous dispersions as a pragmatic method for polymer selection. Reduced crystallization temperature of API, a parameter introduced by Zhou et al.,1 was utilized in this study for rank ordering interactions in API-polymeric systems. The trends in reduced crystallization temperature monitored over polymer concentration range of up to 20% polymer loading were utilized to calculate "crystallization parameter" or CP for two model systems (nifedipine and BI ABC). The rank order of CP, i.e., a measure of API-polymer interaction, for nifedipine followed the order PVP > PVP-VA > Soluplus > HPMCAS > PV Ac > PAA. This rank ordering was correlated to published results of molecular interactions and physical stability for nifedipine. A different rank ordering was observed for BI ABC: PAA > PVP > HPMCAS > Soluplus > PVPV-VA > PVAc. Interactions for BI ABC were not as differentiated when compared to nifedipine based on CP trends. BI ABC dispersions at drug loadings between 40 and 60% were physically stable for prolonged periods under ICH conditions as well as accelerated stress. We propose that large CP differences among polymers could be predictive of stability outcomes. Acceptable stability at pharmaceutically relevant drug loadings would suggest that the relative influence of downstream processes, such as polymer solubility in various solvents, process suitability and selection, and more importantly supersaturation potential, should be higher compared to stability considerations while developing compounds like BI ABC.
authors.affiliation: Pharmaceutical Development, Boehringer-Ingelheim Pharmaceuticals Inc. , Ridgefield, Connecticut 06877, United States.
authors.forename: Chandan
authors.initials: C
authors.lastname: Bhugra
authors.affiliation: Pharmaceutical Development, Boehringer-Ingelheim Pharmaceuticals Inc. , Ridgefield, Connecticut 06877, United States.
authors.forename: Chitra
authors.initials: C
authors.lastname: Telang
authors.affiliation: Pharmaceutical Development, Boehringer-Ingelheim Pharmaceuticals Inc. , Ridgefield, Connecticut 06877, United States.
authors.forename: Robert
authors.initials: R
authors.lastname: Schwabe
authors.affiliation: Pharmaceutical Development, Boehringer-Ingelheim Pharmaceuticals Inc. , Ridgefield, Connecticut 06877, United States.
authors.forename: Li
authors.initials: L
authors.lastname: Zhong
mesh_terms: D003460:Crystallization; D004355:Drug Stability; D009543:Nifedipine / Q000737:chemistry; D011108:Polymers / Q000737:chemistry*; D011145:Polyvinyls / Q000737:chemistry; D011759:Pyrrolidines / Q000737:chemistry; D013696:Temperature; D044366:Transition Temperature
chemical_list: D011108:Polymers; D011145:Polyvinyls; D011759:Pyrrolidines; C505150:poly(N-vinylpyrrolidine); D009543:Nifedipine
keywords: amorphous; crystallization; physical stability; polymer selection; reduced crystallization temperature